VPC-70619
VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer)[2].
Product Specifications
CAS Number
2361742-30-3
UNSPSC
12352005
Target
C-Myc
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vpc-70619.html
Purity
99.93
Solubility
DMSO : ≥ 100 mg/mL
Smiles
N#CC1=CC(C(F)(F)F)=C(C=C1)NNC(C2=CC=C(C(Cl)=C2)C#N)=O
Molecular Formula
C16H8ClF3N4O
Molecular Weight
364.71
References & Citations
[1]Ton AT, et al. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. Int J Mol Sci. 2022;23 (5) :2588. Published 2022 Feb 26. |[2]Molteni E, et al. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation. Int J Mol Sci. 2023 Mar 22;24 (6) :5993.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC681171-100 1x 100 µL
CD34 (HPCA1/1171), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
